Wolverine Trading
CHRS icon

Wolverine Trading’s Coherus Oncology CHRS Stock Holding History

Wolverine Trading’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$66.8K Buy
39,300
+5,700
+17% +$6.34K ﹤0.01% 5345
2025
Q2 		$25K Buy
33,600
+7,300
+28% +$6.3K ﹤0.01% 4454
2025
Q1 		$22.1K Sell
26,300
-32,500
-55% -$37.4K ﹤0.01% 4552
2024
Q4 		$88.2K Buy
58,800
+47,400
+416% +$53.2K ﹤0.01% 4834
2024
Q3 		$12K Sell
11,400
-7,400
-39% -$10.1K ﹤0.01% 4672
2024
Q2 		$32.5K Buy
18,800
+2,000
+12% +$4.03K ﹤0.01% 4276
2024
Q1 		$40.2K Sell
16,800
-15,500
-48% -$38.1K ﹤0.01% 4256
2023
Q4 		$108K Sell
32,300
-7,700
-19% -$20.6K ﹤0.01% 4088
2023
Q3 		$150K Buy
40,000
+5,900
+17% +$27.3K ﹤0.01% 3863
2023
Q2 		$143K Buy
34,100
+7,300
+27% +$43.1K ﹤0.01% 3650
2023
Q1 		$172K Buy
26,800
+9,900
+59% +$76.8K ﹤0.01% 3484
2022
Q4 		$134K Buy
+16,900
New +$130K ﹤0.01% 3318
2022
Q1 		– Sell
-12,800
Closed -$214K – 5503
2021
Q4 		$214K Buy
+12,800
New +$224K ﹤0.01% 4604
2021
Q3 		– Sell
-10,400
Closed -$146K – 6310
2021
Q2 		$146K Buy
+10,400
New +$147K ﹤0.01% 5213
2019
Q1 		– Sell
-10,200
Closed -$91K – 4588
2018
Q4 		$91K Sell
10,200
-1,400
-12% -$16.2K ﹤0.01% 4006
2018
Q3 		$191K Buy
+11,600
New +$206K ﹤0.01% 4284
2018
Q1 		– Sell
-12,900
Closed -$114K – 5137
2017
Q4 		$114K Sell
12,900
-1,900
-13% -$20.3K ﹤0.01% 4411
2017
Q3 		$198K Sell
14,800
-10,800
-42% -$143K ﹤0.01% 3821
2017
Q2 		$370K Buy
+25,600
New +$492K ﹤0.01% 2747

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wolverine Trading's CHRS Position: Q3 2025 in Review

Wolverine Trading increased its Coherus Oncology (CHRS) stake by 71% in Q3 2025, buying an estimated $14.1K and bringing the position to 30,360 shares worth $51.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5405.

Wolverine Trading first reported a position in CHRS in Q2 2017 and has held it in 11 quarters since. The position peaked at $367K in Q4 2019. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Wolverine Trading held 30,360 shares of Coherus Oncology worth $51.6K as of Q3 2025.
  • Wolverine Trading bought 12,657 Coherus Oncology shares in Q3 2025, an estimated $14.1K.
  • Coherus Oncology made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5405 holding.
  • Wolverine Trading first reported a position in Coherus Oncology in Q2 2017 and has held it in 11 quarters since.
  • Wolverine Trading's Coherus Oncology position peaked at $367K in Q4 2019.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.